Overview

Angiotensin II in General Anesthesia

Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
Hypotension in adult patients undergoing general anesthesia is common. This can lead to hypoperfusion of vital organs, organ damage, and states of increased metabolic duress. This may be worse in patients with underlying essential hypertension and worse in patients taking Angiotensin Converting Enzyme Inhibitors (ACE) and Angiotensin Receptor Blockers (ARBs). Intravenous (IV) administration of Ang II may be an effective treatment of hypotension in this patient population.
Phase:
Phase 1
Details
Lead Sponsor:
Wake Forest University Health Sciences
Collaborator:
La Jolla Pharmaceutical Company
Treatments:
Anesthetics
Angiotensin II
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Angiotensinogen
Antihypertensive Agents
Enzyme Inhibitors
Giapreza